From clinical research, studies have shown that there was significantly higher level of serum VTN in breast cancer patients with early stage than those in healthy people, patients with benign breast lesions or pre-cancerous lesions, and advanced breast cancer patients. This evidence concerns the gene VTN and breast carcinoma.